62 related articles for article (PubMed ID: 10836767)
1. Does losartan decrease all-cause mortality more than placebo or first-generation ACE inhibitors for patients with moderate to severe heart failure?
LeClair BM
J Fam Pract; 2000 May; 49(5):397. PubMed ID: 10836767
[No Abstract] [Full Text] [Related]
2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
3. [A-II blocker or ACE inhibitor in heart failure? Captopril can't be beat].
Einecke D
MMW Fortschr Med; 1999 Nov; 141(47):4-5. PubMed ID: 10912155
[No Abstract] [Full Text] [Related]
4. Is losartan superior to captopril in reducing all-cause mortality in elderly patients with symptomatic heart failure?
Trojian TH; Jackson EA
J Fam Pract; 2000 Aug; 49(8):759-60. PubMed ID: 10947144
[No Abstract] [Full Text] [Related]
5. ACE inhibitors still the drug of choice for heart failure--and more.
Topol E
Lancet; 1999 Nov; 354(9192):1797. PubMed ID: 10577651
[No Abstract] [Full Text] [Related]
6. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
[TBL] [Abstract][Full Text] [Related]
7. Are angiotensin II receptor antagonists indicated in chronic heart failure?
Komajda M
Heart Fail Monit; 2002; 2(3):85-7. PubMed ID: 12634889
[TBL] [Abstract][Full Text] [Related]
8. [Effect of long-term treatment with enalapril, losartan and their combination on the quality of life of patients with congestive heart failure].
Vizir VA; Berezin AE
Ter Arkh; 2002; 74(1):52-5. PubMed ID: 11878061
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II type 1 receptor blockers and congestive heart failure.
Auer JW; Berent R; Eber B
Circulation; 2001 Oct; 104(15):E82. PubMed ID: 11591633
[No Abstract] [Full Text] [Related]
10. [Therapeutic perspectives: association of ACE inhibitors and angiotensin receptor blockers].
Costantino S; Millozzi F; Scarlata S
Clin Ter; 2001; 152(2):77-8. PubMed ID: 11441526
[No Abstract] [Full Text] [Related]
11. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
[TBL] [Abstract][Full Text] [Related]
12. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker).
Dimopoulos K; Salukhe TV; Coats AJ; Mayet J; Piepoli M; Francis DP
Int J Cardiol; 2004 Feb; 93(2-3):105-11. PubMed ID: 14975535
[TBL] [Abstract][Full Text] [Related]
13. [Angiotensin-II-antagonism: new hope for the management of cardiac insufficiency].
Z Kardiol; 1997 Sep; 86(9 Suppl Angio):1-4. PubMed ID: 9373391
[No Abstract] [Full Text] [Related]
14. Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II).
Konstam MA; Neaton JD; Poole-Wilson PA; Pitt B; Segal R; Sharma D; Dasbach EJ; Carides GW; Dickstein K; Riegger G; Camm AJ; Martinez FA; Bradstreet DC; Ikeda LS; Santoro EP;
Am Heart J; 2005 Jul; 150(1):123-31. PubMed ID: 16084158
[TBL] [Abstract][Full Text] [Related]
15. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Saha SA; Molnar J; Arora RR
Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
[TBL] [Abstract][Full Text] [Related]
17. [Current role of angiotensin II antagonists in the treatment of heart failure].
Porcu M; Orrù P
Ital Heart J Suppl; 2000 Sep; 1(9):1213-4. PubMed ID: 11140296
[No Abstract] [Full Text] [Related]
18. [The ELITE 2 study].
Mahé I
Presse Med; 2000 Sep; 29(25):1407. PubMed ID: 11036516
[No Abstract] [Full Text] [Related]
19. What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?
Dickstein K
Am Heart J; 2003 May; 145(5):754-7. PubMed ID: 12766730
[No Abstract] [Full Text] [Related]
20. [The ACE inhibitor, captopril, in the light of new clinical studies].
Simko F; Simková M; Kovacs L
Ceska Slov Farm; 2002 Mar; 51(2):63-7. PubMed ID: 11928278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
